Venus Medtech (Hangzhou) Inc. is a leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018.
The Company’s self-developed product, VenusA-Valve, is the first transcather aortic heart valve replacement (“TAVR”) product approved by the National Medical Products Administration (“NMPA”) and commercialized in China.
Company’s Keywords:
<39
<65247000
<2009